艾司西酞普兰与文拉法辛缓释剂治疗广泛性焦虑障碍的对照研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (10): 1167-1171.

艾司西酞普兰与文拉法辛缓释剂治疗广泛性焦虑障碍的对照研究

沈仲夏, 关铁峰, 沈鑫华, 钱敏才, 林敏, 杨剑虹

湖州市第三人民医院心身科,湖州 313000,浙江

收稿日期:2012-06-25 修回日期:2012-08-02 发布日期:2012-10-19
通讯作者: 沈鑫华,通信作者,男,主要从事广泛性焦虑及抑郁症等疾病的临床治疗和生物学病因的研究。E-mail: shenxinhuasun@sina.com
作者简介:沈仲夏,男,在读硕士,现主要从事心身医学的临床及发病机制的研究。E-mail: snowszx@sina.com
基金资助:
湖州市科技局攻关计划项目(2010GS07)

The control research of escitalopram vs venlafaxine XR.on the treatment of generalized anxiety disorder

SHEN Zhong-xia, GUAN Tie-feng, SHEN Xing-hua, QIAN Ming-cai, LIN Min, YANG Jian-hong

The Third People's Hospital of Huzhou City , Huzhou 313000, Zhejiang,China

Received:2012-06-25 Revised:2012-08-02 Published:2012-10-19

摘要/Abstract

摘要： 目的: 观察艾司西酞普兰与文拉法辛缓释剂治疗广泛性焦虑障碍的疗效和安全性。方法: 将74例符合《国际疾病与相关健康问题统计分类(ICD)第10版》(ICD-10)广泛性焦虑障碍的患者随机分成艾司西酞普兰组(n=38)和文拉法辛缓释剂组(n=36),治疗持续8周,用汉密尔顿焦虑量表(HAMA)评定患者焦虑症状及疗效,用汉密尔顿抑郁量表(HAMD)评定患者的抑郁症状,同时用不良反应量表(TESS)和实验室检查评估治疗安全性。结果: 治疗1周末两组HAMA评分开始明显下降(P<0.01),第1、2、4周末艾司西酞普兰组HAMA减分率明显高于文拉法辛缓释剂组(P<0.05),但是第8周末两组的减分率无统计学差异(P>0.05)。8周末两组的治愈率分别为 60.5%和 66.7%,有效率分别为78.9%和 86.1%,文拉法辛缓释剂组显著高于艾司西酞普兰组(P<0.01)。8周末两组HAMD评分较治疗前也均有明显下降(P<0.01)。两组不良反应差异无统计学意义(P>0.05)。结论: 文拉法辛缓释剂治疗广泛性焦虑总体疗效优于艾司西酞普兰,但是艾司西酞普兰起效快于文拉法辛缓释剂,两者安全性无明显差异。

关键词: 艾司西酞普兰, 文拉法辛缓释剂, 广泛性焦虑障碍

Abstract: AIM: To observe the efficacy and safety of escitalopram and venlafaxine on the treatment of generalized anxiety disorder(GAD) patients. METHODS: 74 patients who met the ICD-10 criteria for GAD were divided into escitalopram group(n=38) and venlafaxine group(n=36) randomly. The trial lasted 8 weeks. The anxiety status and efficacy was evaluated with HAMA at the baseline, 1^st, 2^th, 4^th and 8^th weekend respectively while the depression status was evaluated by HAMD,and the safety was evaluated by TESS and laboratory examination.RESULTS: The HAMA scores of both group declined significantly by the end of 1st week(P<0.01), and the reduction of HAMA scores in the escitalopram group were larger than those in venlafaxine group at the end of 1^st, 2^th and 4^th weekend(P<0.05), while there were no significant difference between the two groups at the end of 8^th weekend(P>0.05). There were significant difference within the remission rate 60.5% vs 66.7%, and response rate 78.9% vs 86.1% between the two groups(P<0.01). The HAMD scores decreased significantly after 8 weeks treatment in both groups(P<0.01). The side effects of both groups had no significant difference(P>0.05). CONCLUSION: Either escitalopram or venlafaxine would be effective for GAD, but it seemed that venlafaxine was more effective than escitalopram, and escitalopram responses faster, while the safety was similar.

Key words: Escitalopram, Venlafaxine, Generalized anxiety disorder

中图分类号:

R749.7

沈仲夏, 关铁峰, 沈鑫华, 钱敏才, 林敏, 杨剑虹. 艾司西酞普兰与文拉法辛缓释剂治疗广泛性焦虑障碍的对照研究[J]. 中国临床药理学与治疗学, 2012, 17(10): 1167-1171.

SHEN Zhong-xia, GUAN Tie-feng, SHEN Xing-hua, QIAN Ming-cai, LIN Min, YANG Jian-hong. The control research of escitalopram vs venlafaxine XR.on the treatment of generalized anxiety disorder[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1167-1171.

参考文献

[1] 吴文源. 焦虑障碍防治指南[M]. 北京:人民卫生出版社,2010:115.
[2] Kessler RC, Berglund P, Demler O, et al.Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication[J]. Arch Gen Psychiatry,2005, 62(6): 593-602.
[3] Ma X, Xiang YT, Cai ZJ, Generalized anxiety disorder in China: prevalence, sociodemographic correlates, comorbidity, and suicide attempts[J].Perspect Psychiatr Care , 2009,45(2):119-127.
[4] Davidson JR,Zhang W,Connor KM,et al.A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)[J].J Psychopharmacol,2008,10(2):1-24.
[5] 吴文源. 焦虑障碍防治指南[M]. 北京:人民卫生出版社,2010:129.
[6] Goodman WK, Bose A, Wang Q, et al.Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials[J]. J Affect Disord,2005,87(2/3):161-167.
[7] Allgulander C, Hackett D, Salinas E .Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study[J]. Br J Psychiatry,2001, 179:15-22.
[8] Davideson JR, Bose A, Kozotzer A, et al.Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled,flexible-dose study[J]. Depress Anxiety, 2004,19(4):234-240.
[9] Gelenberg AJ, Lydiard RB, Rudolph RL, et al.Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial[J]. JAMA ,2000,283: 3082-3088.
[10] 张燕,李功迎,李陨丹,等. 万拉法辛缓释剂与帕罗西汀治疗广泛性焦虑障碍的对照研究[J].中南药学,2009,7(11):150-153.
[11] 李良,杨剑虹,沈鑫华,等.艾司西酞普兰与西酞普兰治疗广泛性焦虑的对照研究[J].上海精神医学,2007,19(6):360-361.
[12] Montgomery SA,Sheehan DV,Meoni P,et al.Characterization of the longitudinal course of improvement ingeneralized anxiety disorder during long-term treatment with venlafaxine XR[J].J Psychiatr Res,2002,36(4):209-217.
[13] Bose A, Korotzer A, Gommoll C, et al, Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder[J]. Depress Anxiety,2008,25(10):854-861.
[14] 司天梅,舒良.关于新抗抑郁药艾司西酞普兰[J].临床精神医学杂志,2007,17(2):68-69.
[15] Chen FH,Larsen MB,Sanchezc,et al.The Senantiomer 0f R,Scitalopram,increases inhibitor binding to the human serotonin transporter by an allosteric mechanism.Comparison with other serotonin transporteR inhibitors[J].Eur Neuropsychopharmacology,2005,15(7):193-198.
[16] Boyer P, Mahé V, Hackett D.Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release[J]. Eur Psychiatry , 2004,19(5) :272-279.
[17] Kennedy SH,Andersen HF,Lam RW.Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR:a meta-anal-ysis[J].J Psychiatry Neurosci,2006,31(2):122-131.
[18] Silverstone PH, Studnitz E, Buller R.Current therapeutic strategies for anxious depressives[J]. Expert Rev Neurother, 2003,3(2):193-201.